In vitro release studies of flurbiprofen from different topical formulations

被引:32
作者
El Gendy, AM [1 ]
Jun, HW
Kassem, AA
机构
[1] Idaho State Univ, Coll Pharm, Dept Pharmaceut Sci, Pocatello, ID 83209 USA
[2] Univ Georgia, Coll Pharm, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA
[3] Al Azhar Univ, Coll Pharm, Dept Pharmaceut, Cairo, Egypt
关键词
flurbiprofen; topical formulations; in vitro membraneless release;
D O I
10.1081/DDC-120005628
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The release profiles of flurbiprofen (F) from different gel and ointment formulations were studied in order to evaluate factors governing the release process. Carbopol 934P (CAB), poloxamer 407 (POL), and eudragit S100 (EUD) gel bases were used, while emulsion (EML) and polyethylene glycol (PEG) ointments were employed. The release studies were conducted using membraneless diffusion cells and lipophilic receptor medium, isopropyl myristate (IPM). The effects of gelling agent concentrations and the initial drug load on drug release were determined. Hydrogels were observed to give higher amounts of drug release than hydrophobic EUD gel and ointments, despite the lower bulk viscosity of these bases. Flurbiprofcn release from CAB gels was 3.06-1.56-fold higher than from other formulations. Over a 4-hr period, the amount of F released was 492.8 and 316.0 mug/cm(2) from 2% CAB and 25% POL gels, while it was 213.05, 168.61, and 160.9 mug/cm(2) from EML, 40% EUD, and PEG bases, respectively. The diffusivity of F in the gel bases was an inverse function of the polymer concentrations over the range of 1-3% CAB, 20-30% POL, and 35-45% EUD gels. Drug release was increased front the bases as the initial F concentration increased over the range 0.25-1.0%, while the diffusion coefficient observed an inverse relationship. The CAB and POL gels could be the vehicles of choice for the rapid release and onset of F after topical application.
引用
收藏
页码:823 / 831
页数:9
相关论文
共 26 条
[1]   PIROXICAM RELEASE FROM DERMATOLOGICAL BASES - INVITRO STUDIES USING CELLULOSE MEMBRANE AND HAIRLESS MOUSE SKIN [J].
BABAR, A ;
SOLANKI, UD ;
CUTIE, AJ ;
PLAKOGIANNIS, F .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1990, 16 (03) :523-540
[2]   FLURBIPROFEN - REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN RHEUMATIC DISEASES [J].
BROGDEN, RN ;
HEEL, RC ;
SPEIGHT, TM ;
AVERY, GS .
DRUGS, 1979, 18 (06) :417-438
[3]  
CHENCHOW PC, 1981, INT J PHARM, V8, P89
[4]   Effect of penetration enhancers on flurbiprofen permeation through rat skin [J].
Chi, SC ;
Park, ES ;
Kim, H .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 126 (1-2) :267-274
[5]  
David A. O., 1990, Topical Drug Delivery Formulations, P1
[6]  
DAVID AO, 1990, TOPICAL DRUG DELIVER, P382
[7]  
ELMAGID SIA, 1990, STP PHARM, V6, P380
[8]  
FREDRIK B, 1982, ACTA PHARM SUEC, V19, P229
[9]   CONTROLLED-RELEASE OF SUBSTITUTED BENZOIC AND NAPHTHOIC ACIDS USING CARBOPOL(R) GELS - MEASUREMENT OF DRUG CONCENTRATION PROFILES AND CORRELATION TO RELEASE RATE KINETICS [J].
FRENCH, DL ;
HAGLUND, BO ;
HIMMELSTEIN, KJ ;
MAUGER, JW .
PHARMACEUTICAL RESEARCH, 1995, 12 (10) :1513-1520
[10]  
Gurol Z, 1996, Pharm Acta Helv, V71, P205, DOI 10.1016/0031-6865(96)00011-8